Gilead has unveiled data from a batch of late-stage trials showing that its investigational HIV therapy bictegravir was non-inferior to ViiV Healthcare’s flagship drug dolutegravir in suppressing levels of the virus. More: Gilead’s HIV drug ‘non-inferior’ to ViiV’s Tivicay Source:
read moreMSD’s Keytruda has now become the first and only immunotherapy to be recommended by the National Institute for Health and Care Excellence as a first and second line treatment for specific populations of patients with lung cancer. More: NICE backs
read moreAmerican Journal of Health-System Pharmacy More: Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March 2017 Source: MDlinx
read moreMeningococcal B vaccine Bexsero has been helping drive revenue growth for GlaxoSmithKline, but now, with a European approval, Pfizer’s Trumenba is set to challenge it in that lucrative market. More: Pfizer’s Trumenba to challenge GlaxoSmithKline's Bexsero with EU nod Source:
read moreA series of potential asset deals could put $50 billion cash in the hands of Novartis CEO Joe Jimenez. While he has said he is looking for manageable deals, the company’s pharma portfolio has gaping holes, and some analysts are
read morePay-for-performance deals have been gaining popularity among drugmakers eager to snag payer favor for their meds, and Harvard Pilgrim has been ready and willing to strike up partnerships. The latest to join hands with the PBM? AstraZeneca. More: AstraZeneca puts
read more© 1994 - 2026 B.M. Pharmaceuticals